Herbacetin Broadly Blocks the Activities of CYP450s by Different Inhibitory Mechanisms

Abstract

Herbacetin is a bioactive flavanol compound that has various pharmacological effects. However, the pharmacokinetic characteristics have not been thoroughly investigated. Previously, we screened a natural compound library and identified herbacetin as a potent CYP blocker. Herein, we aimed to mechanistically determine the inhibitory effects of herbacetin on CYP450 and its potential application. A human liver microsome incubation system was developed based on a UPLC-MS/MS method. Moreover, an in silico docking assay and a human CYP recombinase reaction system were developed and used to investigate binding affinity and inhibitory efficacy. Subsequently, the effects of the combination of herbacetin and sorafenib on HepG2 cells were assessed by MTT and immunoblotting assays. The concentration of sorafenib and its main metabolite were measured by UPLC-MS/MS after incubation with or without herbacetin. As a result, we found herbacetin almost completely inhibited the functions of major CYPs at 100 µM. Moreover, through analysis of the structure-activity relationship, we found 4-, 6-, and 8-hydroxyl were essential groups for the inhibitory effects. Herbacetin inhibited CYP3A4, CYP2B6, CYP2C9, and CYP2E1 in a mixed manner, but non-competitively blocked CYP2D6. These results are in good agreement with the recombinase reaction in vitro results, with an IC₅₀ < 10 µM for each tested isoenzyme. Interestingly, the stimulatory effects of sorafenib on HepG2 cell apoptosis were significantly enhanced by combining with herbacetin, which was associated with increased sorafenib exposure. In summary, herbacetin is a potent inhibitor of a wide spectrum of CYP450s, which may enhance the exposure of drugs in vivo.

Key words

herbacetin - mixed inhibition - non-competitive inhibition - CYP450s - HepG2

Publikationsverlauf

Eingereicht: 04. Dezember 2020

Angenommen nach Revision: 30. April 2021

Artikel online veröffentlicht:
11. Juni 2021

• References

• 1 Bao SS, Wen J, Zheng X, Zhou Q, Qu GE, Chen MJ, Hu GX. Evaluation of the inhibition effects of apatinib on human and rat cytochrome P450. Toxicol Lett 2018; 297: 1-7
• 2 Zhu J, Seo JE, Wang S, Ashby K, Ballard R, Yu D, Ning B, Agarwal R, Borlak J, Tong W, Chen M. The development of a database for herbal and dietary supplement induced liver toxicity. Int J Mol Sci 2018; 19: 2955
• 3 Bailey DG. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol 2010; 70: 645-655
• 4 Li J, Liang Q, Sun G. Interaction between traditional Chinese medicine and anticoagulant/antiplatelet drugs. Curr Drug Metab 2019; 20: 701-713
• 5 Ma BL, Ma YM. Pharmacokinetic herb-drug interactions with traditional Chinese medicine: progress, causes of conflicting results and suggestions for future research. Drug Metab Rev 2016; 48: 1-26
• 6 Sun S, Wang Y, Wu A, Ding Z, Liu X. Influence factors of the pharmacokinetics of herbal resourced compounds in clinical practice. Evid Based Complement Alternat Med 2019; 2019: 1983780
• 7 Suroowan S, Mahomoodally MF. Herbal medicine of the 21st century: A focus on the chemistry, pharmacokinetics and toxicity of five widely advocated phytotherapies. Curr Top Med Chem 2019; 19: 2718-2738
• 8 He SM, Yang AK, Li XT, Du YM, Zhou SF. Effects of herbal products on the metabolism and transport of anticancer agents. Expert Opin Drug Metab Toxicol 2010; 6: 1195-1213
• 9 Hermann R, von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med 2012; 78: 1458-1477
• 10 Foroozesh M, Sridhar J, Goyal N, Liu JW. Coumarins and P450s, studies reported to-date. Molecules 2019; 24: 1620
• 11 Gong L, Zhang CM, Lv JF, Zhou HH, Fan L. Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet Genomics 2017; 27: 337-346
• 12 Chen Q, Zhang T, Wang JF, Wei DQ. Advances in human cytochrome p 450 and personalized medicine. Curr Drug Metab 2011; 12: 436-444
• 13 Yu J, Petrie ID, Levy RH, Ragueneau-Majlessi I. Mechanisms and Clinical significance of pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. food and drug administration in 2017. Drug Metab Dispos 2019; 47: 135-144
• 14 Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I. Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. food and drug administration between 2013 and 2016. Drug Metab Dispos 2018; 46: 835-845
• 15 Stresser DM, Mao J, Kenny JR, Jones BC, Grime K. Exploring concepts of in vitro time-dependent CYP inhibition assays. Expert Opin Drug Metab Toxicol 2014; 10: 157-174
• 16 Dong G, Zhou Y, Song X. In vitro inhibitory effects of bergenin on human liver cytochrome P450 enzymes. Pharm Biol 2018; 56: 620-625
• 17 Kamble SH, Sharma A, King TI, Berthold EC, León F, Meyer PKL, Kanumuri SRR, McMahon LR, McCurdy CR, Avery BA. Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids. Toxicol Lett 2020; 319: 148-154
• 18 Wei XA, Li GH, Wang XL, He JX, Wang XN, Ren DM, Lou HX, Shen T. Chemical constituents from the leaves of Cinnamomum parthenoxylon (Jack) Meisn. (Lauraceae). Biochem Syst Ecol 2017; 70: 95-98
• 19 Fliniaux O, Corbin C, Ramsay A, Renouard S, Beejmohun V, Doussot J, Falguières A, Ferroud C, Lamblin F, Lainé E, Roscher A, Grand E, Mesnard F, Hano C. Microwave-assisted extraction of herbacetin diglucoside from flax (Linum usitatissimum L.) seed cakes and its quantification using an RP-HPLC-UV system. Molecules 2014; 19: 3025-3037
• 20 El-Sayed NH, Awaad AS, Hifnawy MS, Mabry TJ. A flavonol triglycoside from Chenopodium murale . Phytochemistry 1999; 51: 591-593
• 21 Berry LM, Zhao Z. An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. Drug Metab Lett 2008; 2: 51-59
• 22 Kim DJ, Roh E, Lee MH, Oi N, Lim DY, Kim MO, Cho YY, Pugliese A, Shim JH, Chen H, Cho EJ, Kim JE, Kang SC, Paul S, Kang HE, Jung JW, Lee SY, Kim SH, Reddy K, Yeom YI, Bode AM, Dong Z. Herbacetin is a novel allosteric inhibitor of ornithine decarboxylase with antitumor activity. Cancer Res 2015; 76: 1146-1157
• 23 Li L, Sapkota M, Kim SW, Soh Y. Herbacetin inhibits inducible nitric oxide synthase via JNK and nuclear factor-κB in LPS-stimulated RAW264.7 cells. Eur J Pharmacol 2015; 765: 115-123
• 24 Jo S, Kim S, Shin DH, Kim MS. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem 2019; 35: 145-151
• 25 Shimada T, Tanaka K, Takenaka S, Murayama N, Martin MV, Foroozesh MK, Yamazaki H, Guengerich FP, Komori M. Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chem Res Toxicol 2010; 23: 1921-1935
• 26 Ge BK, Zhao L, Li XR, Xu PX, Xue M. Glucuronidation is the dominating in vivo metabolism pathway of herbacetin: Elucidation of herbacetin pharmacokinetics after intravenous and oral administration in rats. J Funct Foods 2018; 40: 659-669
• 27 Qiao Y, Xiang Q, Yuan L, Xu L, Liu Z, Liu X. Herbacetin induces apoptosis in HepG2 cells: Involvements of ROS and PI3K/Akt pathway. Food Chem Toxicol 2013; 51: 426-433
• 28 Ghassabian S, Rawling T, Zhou F, Doddareddy MR, Tattam BN, Hibbs DE, Edwards RJ, Cui PH, Murray M. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. Biochem Pharmacol 2012; 84: 215-223
• 29 Ghassabian S, Gillani TB, Rawling T, Crettol S, Nair PC, Murray M. Sorafenib N-Oxide is an inhibitor of human hepatic CYP3A4. AAPS J 2019; 21: 15
• 30 Gillani TB, Rawling T, Murray M. Cytochrome P450-mediated biotransformation of sorafenib and its N-Oxide metabolite: Implications for cell viability and human toxicity. Chem Res Toxicol 2015; 28: 92-102
• 31 Wang X, Zhang X, Huang X, Li Y, Wu M, Liu J. The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4. Xenobiotica 2016; 46: 651-658
• 32 Bao SS, Wen J, Zheng X, Zhou Q, Qu GE, Chen MJ, Hu GX. Evaluation of the inhibition effects of apatinib on human and rat cytochrome P450. Toxicol Lett 2018; 297: 1-7
• 33 Hu GX, Dai DP, Wang H, Huang XX, Zhou XY, Cai J, Chen H, Cai JP. Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population. Pharmacogenomics 2017; 18: 369-379
• 34 Xu RA, Wen J, Tang P, Wang C, Xie S, Zhang BW, Zhou Q, Cai JP, Hu GX. Functional characterization of 22 CYP3A4 protein variants to metabolize ibrutinib in vitro . Basic Clin Pharmacol Toxicol 2018; 122: 383-387
• 35 Dai DP, Wang YH, Wang SH, Geng PW, Hu LM, Hu GX, Cai JP. In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese han population. Acta Pharmacol Sin 2013; 34: 1449-1456
• 36 Dai DP, Geng PW, Wang SH, Cai J, Hu LM, Nie JJ, Hu JH, Hu GX, Cai JP. In vitro functional assessment of 22 newly identified CYP2D6 allelic variants in the Chinese population. Basic Clin Pharmacol Toxicol 2015; 117: 39-43
• 37 Bai F, Liu X, Li J, Zhang H, Jiang H, Wang X, Li H. Bioactive conformational generation of small molecules: a comparative analysis between force-field and multiple empirical criteria based methods. BMC Bioinformatics 2010; 11: 545
• 38 Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010; 31: 455-461
• 39 Bramucci E, Paiardini A, Bossa F, Pascarella S. PyMod: sequence similarity searches, multiple sequence-structure alignments, and homology modeling within PyMOL. BMC Bioinformatics 2012; 13 (Suppl. 04) S2